Last reviewed · How we verify
Dexamethasone implant
Dexamethasone implant delivers corticosteroid directly to ocular tissues to suppress inflammation and reduce edema.
Dexamethasone implant delivers corticosteroid directly to ocular tissues to suppress inflammation and reduce edema. Used for Macular edema associated with retinal vein occlusion, Uveitis, Diabetic macular edema.
At a glance
| Generic name | Dexamethasone implant |
|---|---|
| Also known as | Ozurdex, OZURDEX®, Dexamethasone implants (Ozurdex®, Allergan Inc., Irvine, CA, USA) |
| Sponsor | Yeungnam University College of Medicine |
| Drug class | Corticosteroid implant |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors in the cytoplasm, translocating to the nucleus to modulate gene expression and suppress inflammatory mediators. The implant formulation provides sustained local release of the drug to the eye, achieving high intraocular concentrations while minimizing systemic exposure. This mechanism reduces inflammatory cell infiltration, cytokine production, and vascular permeability in conditions characterized by ocular inflammation and edema.
Approved indications
- Macular edema associated with retinal vein occlusion
- Uveitis
- Diabetic macular edema
Common side effects
- Elevated intraocular pressure
- Cataract progression
- Conjunctival hemorrhage
- Endophthalmitis
Key clinical trials
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- Soaked Pharyngeal Packing Agents in Septoplasty (PHASE3)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array (NA)
- Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622) (NA)
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone implant CI brief — competitive landscape report
- Dexamethasone implant updates RSS · CI watch RSS
- Yeungnam University College of Medicine portfolio CI